JP Morgan Chase
SCLN

JP Morgan Chase’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

JP Morgan Chase’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-661,789
Closed -$7.38M – 5732
2017
Q3 		$7.38M Buy
661,789
+15,356
+2% +$169K ﹤0.01% 2249
2017
Q2 		$7.11M Sell
646,433
-38,229
-6% -$382K ﹤0.01% 2227
2017
Q1 		$6.71M Buy
684,662
+213,842
+45% +$2.14M ﹤0.01% 2223
2016
Q4 		$5.08M Buy
470,820
+466,260
+10,225% +$4.66M ﹤0.01% 2449
2016
Q3 		$47K Buy
4,560
+2,984
+189% +$32.5K ﹤0.01% 4053
2016
Q2 		$20K Buy
1,576
+12
+0.8% +$157 ﹤0.01% 4231
2016
Q1 		$17K Buy
1,564
+774
+98% +$6.88K ﹤0.01% 4133
2015
Q4 		$8K Buy
+790
New +$6.61K ﹤0.01% 4265
2014
Q1 		– Sell
-437,723
Closed -$2.21M – 4088
2013
Q4 		$2.21M Sell
437,723
-38,083
-8% -$183K ﹤0.01% 2687
2013
Q3 		$2.41M Sell
475,806
-32,993
-6% -$184K ﹤0.01% 2677
2013
Q2 		$2.52M Buy
+508,799
New +$2.42M ﹤0.01% 2632

JP Morgan Chase's SCLN Position: Q4 2017 in Review

JP Morgan Chase sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 661,789 shares — an estimated $7.38M sold.

JP Morgan Chase first reported a position in SCLN in Q2 2013 and held it in 11 quarters. The position peaked at $7.38M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • JP Morgan Chase reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • JP Morgan Chase sold 661,789 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $7.38M.
  • JP Morgan Chase first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 11 quarters.
  • JP Morgan Chase's Sciclone Pharmaceuticals Inc position peaked at $7.38M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.